# SUPPRESSION OF 12-O-TETRADECANOYLPHORBOL-13-ACETATE INDUCED ORNITHINE DECARBOXYLASE ACTIVITY BY RESVERATROL DERIVATIVES

## Suaib Luqman<sup>1,2</sup>, Tamara P. Kondratyuk<sup>1</sup>, Juma Hoshino<sup>3</sup>, Mark Cushman<sup>3</sup>, John M. Pezzuto<sup>1\*</sup>

College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii 96720, United States. Molecular Bioprospection Department of Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow-226015, India. Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and The Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.



- Resveratrol (3,4,5-trihydroxy-trans-stilbene), a phytoalexin found in grape skins, peanuts, and red wine, have a potent chemopreventive effect in multiple carcinogenesis models both *in vivo* and *in vitro*.
- Resveratrol and its analogues are known to interfere with signal transduction pathways, where they inhibit activities of various protein kinases which in turn declines the expression of nuclear proto-oncogenes and the activity of ornithine decarboxylase (ODC) is reduced.








Spermidine

Putrescine

- ODC activity and expression have been among the first biomarkers of neoplastic proliferation and catlyzes the rate-limiting step in polyamine biosynthesis.
- ODC activity is essential for cell proliferation and is required for progression into the S phase of the cell cycle.
- TPA induction of ODC mRNA expression and ODC activity may be PKC activation dependent or independent.



Compounds	Inhibition (%)	Survival (%)
JH 2-18	94.27 0.55	68.2 14.3
JH 2-23	90.55 4.49	71.9 17.2
JH 2-44	98.15 0.08	99.5 4.1
JH 2-61	97.85 0.66	56.6 16.7
JH 3-3	96.17 1.3	60.5 19.1
JH-3-37	95.07 0.97	67.0 18.6
JH-3-39	90.8 2.15	66.4 22.9
JH-3-46	96.2 0.44	78.1 11.4
JH-4-15	95.12 0.41	74.4 8.7
JH-4-58	93.52 0.14	73.8 3.1
JH-4-56	97.27 0.03	84.4 17.5
JH-4-59	91.07 2.7	89.6 7.1
SB-I-29	90.34 6.5	48.1 12.0
SB-I-35	95.42 0.23	58.0 2.6
SB-I-36	95.35 1.15	64.1 8.0
SB-I-37	95.80 0.58	79.8 5.2
SB-I-42	94.87 2.39	52.9 9.2
SB-I-43	92.26 0.34	58.7 25.0
SB-I-45	93.49 3.92	77.7 6.3
SB-I-49	97.86 0.45	94.9 30.2
SB-I-54	47.62 7.2	53.4 10.5
	07 70 0 04	

Resveratrol	96.09	1.82	99.1	11.7
SB-I-56	97.78	0.24	62.6	14.9

### CONCLUSION

- \* Our studies depicts potential metabolites having greater activity [tetrabutylammonium (E)-4-(3,5-dihydroxystyryl)phenyl sulfate (IC50 1.2 μM), resveratrol tripotassium 3,5,4'-trisulfate (IC50 1.8 µM), resveratrol tripotassium 3,4'-disulfate (IC50 1.8 µM), and resveratrol tripotassium 3,5-disulfate (IC50 2.3 µM)], than the resveratrol on human bladder epithelial carcinoma HTB-24 cells in culture
- TPA-increased amount of ODC mRNA may be the result of enhanced ODC gene transcription and/or decreased degradation of ODC mRNA.
- Ouring ODC induction by TPA, the increase in its mRNA is usually much less than the observed activity, suggesting that some regulation of ODC activity occurs posttranscriptionally.
- \* Some of the resveratrol derivatives, doesnot show any significant inhibition of PKC activity although inhibiting the ODC activity at very low concentration of 1.2µM, suggesting their mode of action which is PKC independent.

### Inhibition of PKC activity

- JH 2-23 showed maximum inhibition of PKC activity \*\*
- The inhibition of PKC activity: SB I-36> JH 2-44>SB I-56= SB I-54=SB I-43> SB I-45> JH 3-39= JH 3-37= JH 4-58> JH 3-3 = SB I-37 > JH 4-59=SB I-42= SB I-49=JH 2-61=SB I-29> SB I-35=JH 3-46.

### ACKNOWLEDGEMENT

- Indo-US Science and Technology Forum (IUSSTF), New Delhi
- National Cancer Institute, USA (Project PA 01 CA48112)